Kodiak Sciences Inc. Kodiak Sciences Inc.

Kodiak Sciences Inc.

KOD

Kedudukan dalam Saham #3122
Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical... Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering, advancing, and bringing to market treatments for various conditions affecting the retina. Their primary drug candidate, KSI-301, is an anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer. This compound is currently undergoing Phase IIb/III clinical trials, targeting illnesses such as wet age-related macular degeneration (AMD), diabetic macular edema, previously untreated macular edema resulting from retinal vein occlusion, and non-proliferative diabetic retinopathy. In its earlier, preclinical development pipeline, the company is also working on KSI-501, a bispecific conjugate designed for retinal conditions involving inflammation, and KSI-601, a triplet inhibitor aimed at addressing dry AMD. Established in 2009, this Palo Alto, California-based company operated under the name Oligasis, LLC before rebranding as Kodiak Sciences Inc. in September 2015.
Harga Saham
$93.93
Modal Pasaran
$5.90B
Perubahan (1 hari)
2.82%
Perubahan (1 tahun)
430.65%
Negara
US
Perdagangan Kodiak Sciences Inc. (KOD)

Kategori

Healthcare
Nisbah P/B bagi Kodiak Sciences Inc. (KOD)
Nisbah P/B pada October 2026 TTM: 83.12
Menurut laporan kewangan dan harga saham terkini Kodiak Sciences Inc., nisbah P/B semasa (TTM) ialah 83.12. Pada akhir 2023, nisbah P/B syarikat ialah 0.60.
Sejarah nisbah P/B untuk Kodiak Sciences Inc. dari 2016 hingga 2026
Nisbah P/B pada akhir setiap tahun
Tahun Nisbah P/B Ubah
2026 (TTM) 83.12 2,288.62%
2024 3.48 480.70%
2023 0.60 -30.10%
2022 0.86 -35.23%
2021 1.32 -15.19%
2020 1.56 -1.01%
2019 1.58 168.87%
2018 0.59 -174.79%
2017 -0.78 113.24%
2016 -0.37 0.00%
Nisbah P/B untuk syarikat atau pesaing yang serupa
Syarikat Nisbah P/B Perbezaan Nisbah P/B Negara
6.251 -92.48%
US
13.2547 -84.05%
US
4.208 -94.94%
AU
- -
CH
6.1824 -92.56%
NL